Rigel Pharmaceuticals (RIGL) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.88
- EPS estimate
- $0.09
- EPS surprise
- +903.42%
- Revenue surprise
- +42.39%
- Revenue
- $78.7M
- Revenue estimate
- $55.3M
- Reported
- Aug 4, 2026
Rigel Pharmaceuticals reported Q2 2026 results on August 4, 2026. Earnings per share were $0.88, far above the $0.09 estimate, a 903.42% beat. Revenue of $78.7 million was about 42% above the $55.3 million consensus. Compared with Q2 2025, though, EPS fell about 73% from $3.28 and revenue fell about 23% from $101.7 million.
The table shows a shift from losses to profits. Rigel lost money in 10 of the 20 quarters shown, the last in Q2 2024. It has been profitable in each of the eight quarters since. Annual EPS went from a $3.40 loss in 2022 and a $1.50 loss in 2023 to a $0.94 profit in 2024 and $18.91 in 2025. Most of the 2025 figure came from an unusually large Q4 2025, at $13.54 per share. Annual revenue rose from $116.9 million in 2023 to $294.3 million in 2025. Rigel beat the EPS estimate in 15 of the 20 quarters shown.
Rigel reported its third quarter between November 2 and November 7 in each of the past five years. That points to early November 2026 for Q3 2026. It will show how results compare with the $1.46 per share earned in Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.09 | $0.88 | +903.42% | $78.7M | SEC |
| Q1 2026 | May 5, 2026 | $0.80 | $0.44 | −44.67% | $58.8M | SEC |
| Q4 2025 | Mar 3, 2026 | $1.20 | $13.54 | +1026.92% | $69.8M | SEC |
| Q3 2025 | Nov 4, 2025 | $0.90 | $1.46 | +62.28% | $69.5M | SEC |
| Q2 2025 | Aug 5, 2025 | $2.58 | $3.28 | +27.13% | $101.7M | SEC |
| Q1 2025 | May 6, 2025 | $0.09 | $0.63 | +605.49% | $53.3M | SEC |
| Q4 2024 | Mar 4, 2025 | $0.45 | $0.80 | +77.46% | $57.6M | SEC |
| Q3 2024 | Nov 7, 2024 | $0.06 | $0.70 | +1096.58% | $55.3M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.29 | −$0.06 | +79.46% | $36.8M | SEC |
| Q1 2024 | May 7, 2024 | −$0.29 | −$0.50 | −73.61% | $29.5M | SEC |
| Q4 2023 | Mar 5, 2024 | −$0.20 | $0.00 | +100.00% | $35.8M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.71 | −$0.30 | +57.74% | $28.1M | SEC |
| Q2 2023 | Aug 1, 2023 | −$0.78 | −$0.40 | +48.74% | $26.9M | SEC |
| Q1 2023 | May 2, 2023 | −$0.96 | −$0.80 | +16.48% | $26.1M | SEC |
| Q4 2022 | Mar 7, 2023 | −$0.95 | $0.10 | +110.56% | $51.3M | SEC |
| Q3 2022 | Nov 3, 2022 | −$1.32 | −$1.10 | +16.80% | $22.4M | — |
| Q2 2022 | Aug 2, 2022 | −$1.23 | −$0.80 | +34.79% | $29.8M | — |
| Q1 2022 | May 3, 2022 | −$1.37 | −$1.60 | −16.81% | $16.7M | — |
| Q4 2021 | Mar 1, 2022 | −$1.27 | −$1.30 | −2.51% | $20.4M | — |
| Q3 2021 | Nov 2, 2021 | −$1.00 | −$1.20 | −20.43% | $21.5M | — |
Quarterly revenue
Frequently asked questions
When did Rigel Pharmaceuticals (RIGL) last report earnings?
Rigel Pharmaceuticals last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did RIGL beat earnings estimates?
Yes. Rigel Pharmaceuticals reported EPS of $0.88 for Q2 2026 against a $0.09 estimate — a 903.42% beat.
How much revenue did RIGL report last quarter?
Rigel Pharmaceuticals reported $78.7M in revenue for Q2 2026, against a consensus estimate of $55.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.